{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:09:25Z","timestamp":1793772565255,"version":"4.6.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To compare the treatment outcomes of gemcitabine with nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX; a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) for metastatic pancreatic cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed consecutive patients with metastatic or recurrent pancreatic cancer treated with GnP or mFFX as the first-line chemotherapy between March 2014 and December 2019 in our hospital. Treatment outcomes were compared using propensity score matching to adjust for age, sex, performance status, carcinoembryonic antigen levels, carbohydrate antigen 19-9 levels, and disease status (metastatic or recurrent).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Five hundred sixty-eight patients were included (GnP\/mFFX, 456\/112). After propensity score matching, 218 patients were extracted. The median age was around 61 years, and the proportion of performance status 0 was approximately 90%. The median overall survival values were 14.6 and 15.5 months (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.45), and the median progression-free survival was 7.4 months (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.53) for GnP and mFFX, respectively. The disease control rates were higher in the GnP group (82.6% vs 67.9%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02). In nonhematologic adverse events, grade 3\/4 anorexia and diarrhea occurred significantly more frequently in the mFFX group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Gemcitabine with nab-paclitaxel had a higher disease control rate and lower rates of severe anorexia and diarrhea in our propensity-matched population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001801","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:00:46Z","timestamp":1620072046000},"page":"595-601","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Takafumi","family":"Mie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250812","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"bib3-20250812","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","year":"2014","journal-title":"Cancer Res"},{"key":"bib4-20250812","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","year":"2016","journal-title":"World J Gastroenterol"},{"key":"bib5-20250812","doi-asserted-by":"crossref","first-page":"271","DOI":"10.21873\/invivo.11471","article-title":"Improvement of treatment outcomes for metastatic pancreatic cancer: a real-world data analysis","volume":"33","year":"2019","journal-title":"In Vivo"},{"key":"bib6-20250812","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib7-20250812","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib8-20250812","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer","volume":"81","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib9-20250812","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","year":"2016","journal-title":"Br J Cancer"},{"key":"bib10-20250812","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2017.07.012","article-title":"Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population","volume":"406","year":"2017","journal-title":"Cancer Lett"},{"key":"bib11-20250812","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MPA.0000000000001484","article-title":"A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer","volume":"49","year":"2020","journal-title":"Pancreas"},{"key":"bib12-20250812","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib14-20250812","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'ezr' for medical statistics","volume":"48","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"bib15-20250812","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/CMAR.S126073","article-title":"Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US COMMUNITY SETTING","volume":"9","year":"2017","journal-title":"Cancer Manag Res"},{"key":"bib16-20250812","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40801-018-0137-x","article-title":"Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting","volume":"5","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"bib17-20250812","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s12325-018-0784-z","article-title":"Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States","volume":"35","year":"2018","journal-title":"Adv Ther"},{"key":"bib18-20250812","doi-asserted-by":"crossref","first-page":"1756284819878660","DOI":"10.1177\/1756284819878660","article-title":"Folfirinox versus gemcitabine\/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study","volume":"12","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"bib19-20250812","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4251\/wjgo.v12.i2.182","article-title":"FOLFIRINOX vs gemcitabine\/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study","volume":"12","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"bib20-20250812","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10637-018-0598-5","article-title":"Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis","volume":"36","year":"2018","journal-title":"Invest New Drugs"},{"key":"bib21-20250812","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pan.2018.10.003","article-title":"Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe","volume":"19","year":"2019","journal-title":"Pancreatology"},{"key":"bib22-20250812","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12885-020-06945-8","article-title":"Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer","volume":"20","year":"2020","journal-title":"BMC Cancer"},{"key":"bib23-20250812","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"bib24-20250812","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","year":"2015","journal-title":"Nature"},{"key":"bib25-20250812","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","year":"2014","journal-title":"Br J Cancer"},{"key":"bib26-20250812","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib27-20250812","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:06:40Z","timestamp":1754957200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001801"}},"subtitle":["Propensity Score Matching"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001801","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}